CEMIC - CONICET 26185
CENTRO DE EDUCACION MEDICA E INVESTIGACIONES CLINICAS "NORBERTO QUIRNO"
Unidad Ejecutora - UE
artículos
Título:
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
Autor/es:
BRADLEY, WALTER G.; MASCIAS, JAVIER; MOUSSY, ALAIN; LUDOLPH, ALBERT C.; CHAVERRI, DELIA; GAMEZ, JOSEP; MANSFIELD, COLIN D.; MORA, JESUS S.; HERNÁNDEZ-BARRAL, MARÍA; GARGIULO-MONACHELLI, GISELLA M.; HERMINE, OLIVIER
Revista:
Therapeutic Advances in Neurological Disorders
Editorial:
SAGE Publications Ltd
Referencias:
Año: 2021 vol. 14
ISSN:
1756-2856
Resumen:
Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of
